Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | PKM | P14618 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | FAAH | O00519 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | HTR2B | P41595 | 2/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4654834 | 0.88 | TAS2R14 (0.43) | L3MBTL1PKMLMNAMEN1KMT2A | |
| SCHEMBL4653433 | 0.88 | MEN1 (0.56) | LMNAMEN1KMT2AHPGD | |
| SCHEMBL5523733 | 0.84 | L3MBTL1 (0.59) | L3MBTL1PKMLMNAMEN1KMT2A | |
| SCHEMBL5523736 | 0.84 | L3MBTL1 (0.59) | L3MBTL1PKMLMNAMEN1KMT2A | |
| SCHEMBL4654593 | 0.84 | MAPK1 (0.48) | L3MBTL1LMNAMEN1KMT2A | |
| SCHEMBL13929453 | 0.81 | ALDH1A1 (0.55) | L3MBTL1LMNAMEN1KMT2AFAAH | |
| SCHEMBL12404098 | 0.81 | ALDH1A1 (0.55) | L3MBTL1LMNAMEN1KMT2AFAAH | |
| SCHEMBL2171698 | 0.77 | L3MBTL1 (0.69) | L3MBTL1PKMLMNAHPGD | |
| SCHEMBL3515654 | 0.75 | GBA1 (0.53) | L3MBTL1LMNAMEN1KMT2AFAAH | |
| SCHEMBL1662783 | 0.75 | GBA1 (0.53) | L3MBTL1LMNAMEN1KMT2AFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1602354-B1 | Use of polyglutamic acid or its salts | MEIJI SEIKA KAISHA (JP) | 2008-11-05 | — | — | EP | disclosed |
| US-20060165636-A1 | Hair treatment composition and hair cosmetic for damaged hair | MEIJI SEIKA KAISHA, LTD. (JP) | 2006-07-27 | — | — | US | disclosed |
| EP-1602354-A1 | HAIR TREATMENT COMPOSITION AND HAIR COSMETIC FOR DAMAGED HAIR | Meiji Seika Kaisha, Ltd. (JP) | 2005-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060165636-A1 | Hair treatment composition and hair cosmetic for damaged hair | CUTA, COL14A1, PRKDC | L3MBTL1 3668/4885PKM 3215/4885LMNA 2112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.